RVL Pharmaceuticals plc Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
RVL Pharmaceuticals plc reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$23.89 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2023-08-14
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-06-30 was -$23.89M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-03-31 was -$11.61M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-12-31 was -$18.32M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-09-30 was -$14.45M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$51.69M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$64.92M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$79.59M.
- RVL Pharmaceuticals plc net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was -$109.68M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 4 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 5 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 8 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 11 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-30 | -$23.89M 10-Q · filed 2023-08-14 | -$35.50M 10-Q · filed 2023-08-14 | -$53.82M derived: sum of 3 quarters · filed 2023-08-14 | -$68.27M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||||
| 2023-03-31 | -$11.61M 10-Q · filed 2023-08-14 | -$29.93M derived: sum of 2 quarters · filed 2023-08-14 | -$44.38M derived: sum of 3 quarters · filed 2023-08-14 | -$56.48M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||||
| 2022-12-31 | -$18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$32.77M derived: sum of 2 quarters · filed 2023-03-20 | -$44.87M derived: sum of 3 quarters · filed 2023-08-14 | -$51.69M 10-K · filed 2023-03-20 | ||||||||||
| 2022-09-30 | -$14.45M 10-Q · filed 2022-11-10 | -$26.55M derived: sum of 2 quarters · filed 2023-08-14 | -$33.37M 10-Q · filed 2022-11-10 | -$53.09M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||||
| 2022-06-30 | -$12.11M 10-Q · filed 2023-08-14 | -$18.93M 10-Q · filed 2023-08-14 | -$38.65M derived: sum of 3 quarters · filed 2023-08-14 | -$56.51M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||||
| 2022-03-31 | -$6.82M 10-Q · filed 2023-08-14 | -$26.54M derived: sum of 2 quarters · filed 2023-08-14 | -$44.40M derived: sum of 3 quarters · filed 2023-08-14 | -$62.13M derived: sum of 4 quarters · filed 2023-08-14 | ||||||||||
| 2021-12-31 | -$19.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$37.58M derived: sum of 2 quarters · filed 2023-03-20 | -$55.31M derived: sum of 3 quarters · filed 2023-03-20 | -$64.92M 10-K · filed 2023-03-20 | ||||||||||
| 2021-09-30 | -$17.86M 10-Q · filed 2022-11-10 | -$35.59M derived: sum of 2 quarters · filed 2022-11-10 | -$45.20M 10-Q · filed 2022-11-10 | -$100.07M derived: sum of 4 quarters · filed 2022-11-10 | ||||||||||
| 2021-06-30 | -$17.73M 10-Q · filed 2022-11-10 | -$27.34M 10-Q · filed 2022-08-11 | -$27.34M 10-Q · filed 2021-08-16 | -$82.21M derived: sum of 3 quarters · filed 2022-11-10 | -$90.85M derived: sum of 4 quarters · filed 2022-11-10 | |||||||||
| 2021-03-31 | -$9.61M 10-Q · filed 2022-11-10 | -$64.49M derived: sum of 2 quarters · filed 2022-11-10 | -$73.12M derived: sum of 3 quarters · filed 2022-11-10 | -$86.12M derived: sum of 4 quarters · filed 2022-11-10 | ||||||||||
| 2020-12-31 | -$54.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$63.51M derived: sum of 2 quarters · filed 2022-03-30 | -$76.51M derived: sum of 3 quarters · filed 2022-03-30 | -$79.59M 10-K · filed 2022-03-30 | ||||||||||
| 2020-09-30 | -$8.63M 10-Q · filed 2021-11-15 | -$21.63M derived: sum of 2 quarters · filed 2021-11-15 | -$24.71M 10-Q · filed 2021-11-15 | -$51.36M derived: sum of 4 quarters · filed 2021-11-15 | ||||||||||
| 2020-06-30 | -$13.00M 10-Q · filed 2021-11-15 | -$16.08M 10-Q · filed 2021-08-16 | -$16.08M 10-Q · filed 2020-08-11 | -$42.72M derived: sum of 3 quarters · filed 2021-11-15 | -$155.43M derived: sum of 4 quarters · filed 2021-11-15 | |||||||||
| 2020-03-31 | -$3.08M 10-Q · filed 2021-11-15 | -$29.72M derived: sum of 2 quarters · filed 2021-11-15 | -$142.43M derived: sum of 3 quarters · filed 2021-11-15 | -$267.30M derived: sum of 4 quarters · filed 2021-11-15 | ||||||||||
| 2019-12-31 | -$26.64M derived: 8-K 12 month − 10-Q 9 month · filed 2021-09-08 | -$139.35M derived: sum of 2 quarters · filed 2021-09-08 | -$264.21M derived: sum of 3 quarters · filed 2021-09-08 | -$270.90M 8-K · filed 2021-09-08 | ||||||||||
| 2019-09-30 | -$112.70M 10-Q · filed 2020-11-10 | -$112.70M 10-Q · filed 2019-11-14 | -$237.57M derived: sum of 2 quarters · filed 2020-11-10 | -$244.26M 10-Q · filed 2020-11-10 | -$244.26M 10-Q · filed 2019-11-14 | -$346.38M derived: sum of 4 quarters · filed 2020-11-10 | ||||||||
| 2019-06-30 | -$124.87M 10-Q · filed 2020-11-10 | -$124.65M 10-Q · filed 2019-08-08 | -$131.56M 10-Q · filed 2020-08-11 | -$130.85M 10-Q · filed 2019-08-08 | -$233.68M derived: sum of 3 quarters · filed 2020-11-10 | |||||||||
| 2019-03-31 | -$6.69M 10-Q · filed 2020-11-10 | -$6.20M 10-Q · filed 2019-05-09 | -$108.81M derived: sum of 2 quarters · filed 2020-11-10 | |||||||||||
| 2018-12-31 | -$102.12M 10-K · filed 2020-03-19 | -$102.36M 10-K · filed 2019-03-28 | -$109.68M 10-K · filed 2020-03-19 | -$109.40M 10-K · filed 2019-03-28 | ||||||||||
| 2018-10-17 | -$8.84M derived: 10-K 9 month − 10-Q 6 month · filed 2020-03-19 | -$7.56M 10-K · filed 2020-03-19 | -$7.04M 10-K · filed 2019-03-28 | |||||||||||
| 2018-09-30 | -$3.61M 10-Q · filed 2019-11-14 | $2.11M derived: sum of 2 quarters · filed 2019-11-14 | -$2.68M 10-Q · filed 2019-11-14 | -$3.57M 10-Q · filed 2018-11-08 | -$1.59M derived: sum of 4 quarters · filed 2019-12-20 | |||||||||
| 2018-06-30 | $5.71M 10-Q · filed 2019-11-14 | $5.89M 10-Q · filed 2019-08-08 | $1.28M 10-Q · filed 2019-08-08 | $2.01M derived: sum of 3 quarters · filed 2019-12-20 | ||||||||||
| 2018-03-31 | -$4.78M 10-Q · filed 2019-11-14 | -$4.61M 10-Q · filed 2019-05-09 | -$3.70M derived: sum of 2 quarters · filed 2019-12-20 | |||||||||||
| 2017-12-31 | $1.08M derived: 8-K 12 month − 10-Q 9 month · filed 2019-12-20 | -$41.25M 8-K · filed 2019-12-20 | -$41.14M 10-K · filed 2019-03-28 | |||||||||||
| 2017-09-30 | -$42.33M 10-Q · filed 2018-11-08 |